PeproTech Inc.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fruehauf, S.
Right arrow Articles by Ho, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fruehauf, S.
Right arrow Articles by Ho, A. D.
(Journal of Leukocyte Biology. 2003;73:600-603.)
© 2003 by Society for Leukocyte Biology

Imatinib restores expression of CD62L in BCR-ABL-positive cells

S. Fruehauf*, J. Topaly*, M. Schad{dagger}, P. Paschka{ddagger}, H. Gschaidmeier§, W. J. Zeller{dagger}, A. Hochhaus{ddagger} and A. D. Ho*

* Department of Internal Medicine V, University of Heidelberg, Germany;
{dagger} D0200, German Cancer Research Center, Heidelberg, Germany;
{ddagger} III, Medizinische Klinik, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Mannheim, Germany; and
§ Novartis Pharma GmbH, Nürnberg, Germany

Correspondence: Dr. S. Fruehauf, Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, D-69115, Heidelberg, Germany. E-mail: stefan_fruehauf{at}med.uni-heidelberg.de

Chronic myelogenous leukemia (CML) is characterized by aberrant trafficking of malignant hematopoietic progenitor cells in the peripheral blood. Expression of the cell adhesion molecule CD62L was reported to be significantly lower in CML patients than in normal controls. We studied whether the transcription of CD62L in CML cells is dependent on the activity of the BCR-ABL tyrosine kinase. Following addition of the Abelson (ABL) tyrosine kinase inhibitor imatinib (formerly STI571) to two BCR-ABL-positive cell lines (BV173, SD-1), we observed a dose-dependent increase in CD62L RNA levels of up to 45-fold by a quantitative, real-time polymerase chain reaction and an increase in the amount of cell surface-bound CD62L of up to 18-fold by quantitative flow cytometry, respectively. These data are validated by an increased CD62L expression in the bone marrow of patients (n=6) with advanced CML who received imatinib. Restoration of defective cell adhesion mediated via the CD62L pathway may be one mechanism of action of imatinib in BCR-ABL-positive leukemias.

Key Words: chronic myelogenous leukemia • adhesion molecule • L-selectin • imatinib mesylate




This article has been cited by other articles:


Home page
 BloodHome page
L. McCallum, S. Price, N. Planque, B. Perbal, A. Pierce, A. D. Whetton, and A. E. Irvine
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation
Blood, September 1, 2006; 108(5): 1716 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
Blood, June 15, 2004; 103(12): 4666 - 4668.
[Abstract] [Full Text] [PDF]